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Abstract
Background
Nucleic Acid Amplification Tests (NAATs) are the recommended test type for diagnosing
Chlamydia trachomatis (chlamydia). However, less sensitive diagnostic methods—including
direct immunofluorescence (IF) and enzyme-linked immunoassay (ELISA)—remain in use
in lower resourced settings. We estimate the risk of pelvic inflammatory disease (PID) fol-
lowing undiagnosed infection in women tested with non-NAATs and estimate the health
gain from using accurate diagnostic tests.
Methods and findings
We used Denmark’s national Chlamydia Study dataset to extract all chlamydia tests per-
formed in women aged 15–34 years (1998–2001). Tests were categorised as non-NAAT
(IF/ELISA) or NAAT and limited to each woman’s first test in the study period. We linked test
data to hospital presentations for PID within 12 months from the Danish National Patient
Register. The study included 272,105 women with a chlamydia test, just under half (44.78%,
n = 121,857) were tested using NAATs. Overall, 6.38% (n = 17,353) tested positive for chla-
mydia and 0.64% (n = 1,732) were diagnosed with PID within 12 months. The risk of PID fol-
lowing a positive chlamydia test did not differ by test type (NAAT 0.81% [95% CI 0.61–1.00],
non-NAAT 0.78% [0.59–0.96]). The risk of PID following a negative test was significantly
lower in women tested with NAATs compared to non-NAATs (0.55% [0.51–0.59] compared
to 0.69% [0.64–0.73]; adjusted odds ratio (AOR) 0.83 [0.75–0.93]). We estimate that 18% of
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chlamydia infections in women tested with a non-NAAT were undiagnosed and that the risk
of progression from undiagnosed chlamydia infection to PID within 12 months was 9.52%
(9.30–9.68). Using non-NAATs could lead to an excess 120 cases of PID per 100,000
women tested compared to using NAATs. The key limitations of this study are under ascer-
tainment of PID cases, misclassification bias in chlamydia and PID exposure status, bias to
the association between clinical presentation and test type and the presence of unmeasured
confounders (including other sexually transmitted infection [STI] diagnoses and clinical indi-
cation for chlamydia test).
Conclusion
This retrospective observational study estimates the positive impact on women’s reproduc-
tive health from using accurate chlamydia diagnostic tests and provides further evidence for
restricting the use of inferior tests. Women with a negative chlamydia test have a 17% higher
adjusted risk of PID by 12 months if they are tested using a non-NAAT compared to a
NAAT.
Author summary
Why was this study done?
• There are a range of different tests that can be used to diagnose chlamydia infection.
Each of these tests has a different ability to separate the people who are infected with
chlamydia from the people who are not infected.
• If a less sensitive test is used, there is a greater chance that an infection in a person with
chlamydia won’t be detected by the test. In this situation, the individual won’t be treated
and could develop a complication, such as pelvic inflammatory disease, or pass the
infection on to someone else.
• We wanted to test our hypothesis that less sensitive (poorer performing) diagnostic tests
leave a higher proportion of women who are infected with chlamydia undiagnosed and
that this leads to a greater risk of them developing pelvic inflammatory disease within a
year.
What did the researchers do and find?
• We used national administrative healthcare data from Denmark to identify women who
were tested for chlamydia during the period 1998–2001 when less sensitive chlamydia
diagnostic tests (non-NAATs) were gradually replaced by more accurate tests (NAATs).
We added information about any hospital presentations (inpatient, outpatient, or Emer-
gency Department) with pelvic inflammatory disease that women had within a year of
their chlamydia test.
• We used this dataset to compare the proportion of women who went on to be diagnosed
with pelvic inflammatory disease by the type of chlamydia test that they were given
(non-NAAT or NAAT).
Pelvic inflammatory disease following chlamydia testing
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• There were 272,105 women in this study; 6.4% were diagnosed with chlamydia and
0.6% were diagnosed with pelvic inflammatory disease.
• Women who had a positive test and were diagnosed with chlamydia (and presumably
given appropriate treatment for chlamydia) had an equal chance of developing pelvic
inflammatory disease regardless of the diagnostic test type used. But for women who
had a negative test and were not diagnosed with chlamydia, the chance of developing
pelvic inflammatory disease was lower for those who received a more accurate diagnos-
tic test.
• We estimate that almost 1 in 5 women who were infected with chlamydia at the time of
their test, but were tested using the less sensitive non-NAATS, went undiagnosed. This
could lead to an excess 120 cases of PID per 100,000 women tested with a non-NAAT.
What do these findings mean?
• This study has quantified the positive impact on women’s reproductive health from
using accurate chlamydia diagnostic tests and provides further evidence for restricting
the use of inferior tests.
Introduction
Sexually transmitted C. trachomatis (chlamydia) is the most prevalent sexually transmitted
infection (STI) with an estimated 68,455,000 incident cases globally in women in 2012 [1,2].
Chlamydia is the subject of intensive control efforts in many high-income settings [3]. The
aim of diagnosing and treating chlamydia is 2-fold: to reduce the risk of progression to compli-
cations in the individual (including pelvic inflammatory disease [PID]) and to reduce the risk
of transmission to another individual (including neonates).
The method of chlamydia diagnosis has advanced over time. Antigen-based diagnostic tests
were introduced in the 1980s to replace culture [4]. Some of these antigen-based tests were rel-
atively labour intensive and nucleic acid amplification tests (NAATs) were developed and
increasingly robotized to increase the volume of tests that could be undertaken. The additional
advantage of NAATs is that they have a real-world sensitivity of 90%–96%, which leads to a
lower proportion of untreated infections (false negative tests) compared to antigen-based
methods (direct immunofluorescence (IF) or direct fluorescent antibody (DFA) and enzyme-
linked immunosorbent assay (ELISA) or enzyme immunoassay (EIA) sensitivity 65%–75%
compared to NAAT) [5,6].
To minimise the risk of undertreatment due to false negative tests, NAATs have been the
recommended test type for the diagnosis of chlamydia since the early 2000s [7–9]. However,
antigen-based methods remain in use in many settings, often due to resource constraints.
They are also widely available for purchase online and sold over the counter in pharmacies,
including for home testing [3]. The cost and availability of ASSURED (affordable, sensitive,
specific, user-friendly, rapid and robust, equipment-free, and delivered to end-users) diagnos-
tic tests also hampers the implementation of chlamydia case management guidelines in low-
and middle-income settings [2]. The WHO recommends syndromic management of vaginal
Pelvic inflammatory disease following chlamydia testing
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discharge for low-resource settings and this has been widely implemented where expensive
diagnostic tests are not available [10–13].
There are important health consequences from less sensitive diagnostic tests and syndromic
diagnosis. Infected people with false negative tests are falsely reassured, undiagnosed,
untreated, and remain at risk of complications and onward transmission of chlamydia whilst
uninfected people with false positive tests are incorrectly diagnosed and given unnecessary
treatment.
We hypothesise that the increased risk of undiagnosed chlamydia infection following the
use of non-NAATs will lead to an observable higher risk of PID in women who test negative
using non-NAATs compared to NAATs. We aim to estimate the risk of PID following an
undiagnosed chlamydia infection in women tested with a non-NAAT.
Methods
Ethics statement
The Danish Chlamydia Study was approved by the Danish Data Protection Agency (J.nr.
2010-41-4866, J.nr. 2012-331-0228 and J.nr. 2015-41-4344).
Study design
The Danish Chlamydia study is a purpose-generated dataset of all chlamydia tests performed
in public health laboratories in Denmark (including Greenland) between 1st January 1992 and
2nd November 2011. A full description of this dataset has been previously published [14]. For
the present study we extracted all chlamydia test records from women aged 15–34 years that
were performed between 1st January 1998 and 31st December 2001, the interval when non-
NAATs were replaced by NAATs as the most common test type (S1 Fig). In Denmark, the
contribution of NAATs to all non-NAAT/NAAT chlamydia tests was 23.5% in 1998 and
66.01% in 2001, and there were 696,987 female residents aged 15–34 years in 2000 [15]. Clini-
cal Microbiology Laboratories (CMLs) switched from non-NAATs to NAATs at individually
determined times, with the change-over occurring during the study period for most CMLs.
The choice of chlamydia test was made by the CML not by the requesting clinicians and there
were no changes to recommendations for chlamydia testing during the study period.
We excluded chlamydia tests that: (a) had an ambiguous result (defined as not positive or
negative e.g., “inconclusive” or missing data) or (b) used a test type other than NAAT (defined
as PCR, SDA, TMA, LCR, DNA, DNA/RNA) or non-NAAT (defined as ELISA, IF, “antigen”)
(examples of excluded test types: unknown, microscopy, culture). We then limited the dataset
to the first chlamydia test per woman in this time interval (the index test), preferentially select-
ing positive tests and NAATs if multiple tests were performed on the same date.
We linked chlamydia test records to hospital healthcare records from the Danish National
Patient Register (1993–2012) using the study ID number, which is anonymously linked to the
unique Danish patient identification number (key held securely and not accessible to research-
ers) that is recorded in all administrative healthcare records [16]. Each woman’s first recorded
healthcare presentation (outpatient, emergency department, and inpatient) for PID was identi-
fied (defined as International Classification of Diseases version 10 (ICD-10) A181; A514;
A527; A542; A561; N70-748, ICD-10 coding introduced in Denmark in 1994). Episodes of
PID were defined as “previous” if they occurred before the index chlamydia test, “same day” if
they occurred on the same date as the index chlamydia test, and “12 months” if they occurred
between one and 365 days after the index test. We excluded women who had a history of PID
before their index chlamydia test and women who were diagnosed with PID on the same day
as their index test.
Pelvic inflammatory disease following chlamydia testing
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We defined a priori exposure categories as follows: age at chlamydia test (15–24 years; 25–
34 years), year of chlamydia test (1998/1999 and 2000/2001) and chlamydia test positivity (yes/
no). Following peer review, we defined two additional explanatory variables: location of the
laboratory processing the chlamydia test, defined as (a) STI clinic within their catchment (yes/
no), (b) “no” STI clinic as a single group with “yes” STI clinic divided into the five separate lab-
oratories; repeat chlamydia test, defined using the method outlined above and limited to tests
performed30 and365 days after the index test and1 day before a PID diagnosis catego-
rised as no/negative/positive. We also categorised age and year into multiple categories and as
continuous variables.
Statistical analysis
For the cohort overall and by chlamydia test type we describe age, year, chlamydia test positiv-
ity, laboratory area, repeat chlamydia test, and incidence of PID by 12 months. We used Chi-
squared tests to compare the proportion of women in each category by chlamydia test type.
We estimated the risk of PID following an undiagnosed chlamydia infection in women
tested using a non-NAAT. To do this, we estimated “i” the proportion of women tested with a
non-NAAT who had an undiagnosed infection, under the assumption that NAAT positivity is
equal to true population chlamydia positivity (where i = [NAAT positivity] − [non-NAAT pos-
itivity]) and “j” the excess proportion of women tested with a non-NAAT who were diagnosed
with PID (where j = [risk of PID following a non-NAAT]–[risk of PID following a NAAT]).
We then make the assumption that all the observed excess cases of PID in women tested with a
non-NAAT (j) occurred in the proportion with an undiagnosed chlamydia infection (i) to esti-
mate “p” the risk of PID following an undiagnosed chlamydia infection in women tested using
a non-NAAT (where p = [j]/[i]). Finally we estimate “r”, the number of excess cases of PID
that would be observed per 100,000 women tested using a non-NAAT compared to a NAAT
(where r = [i][p]100,000).
We used logistic regression to determine the association between chlamydia test type and
PID by 12 months adjusted for age, year, and laboratory area. We repeated the analysis strati-
fied by chlamydia test result due to the known difference in the performance of NAAT and
non-NAAT diagnostic tests. For each sub-cohort, we compared the risk of PID at 12 months
by test type using a difference between two proportions test and adjusted logistic regression
analysis. We then repeated this logistic regression analysis including repeat chlamydia test as
an explanatory variable. PID is a relatively rare event in this cohort, therefore we refer to the
resulting odds of PID as “risks” in the results and discussion because probability is a more nat-
ural measure.
Results
Generation of the study dataset is illustrated in Fig 1. There were 272,105 women resident in
Denmark aged 15–34 years who had an eligible chlamydia test during the study period (1998–
2001) and no documented previous history of PID. The mean age of women on the date of their
index chlamydia test (i.e., at entry to the study cohort) was 24.80 years (standard deviation 5.06,
range 15–34 years). Under half of this cohort were tested using a NAAT (n = 121,857, 44.78%),
and overall, chlamydia test positivity was 6.38% (n = 17,353) (Table 1). A repeat chlamydia test
was performed in 61,890 women, of which 5.63% (n = 3,484) were positive. The five laboratories
with an STI clinic in their catchment area performed 76.20% (n = 207,331) of the index chla-
mydia tests. Two of these five laboratories did not perform non-NAATs during the study period
(S1 Table). Compared to women tested using a non-NAAT, women tested using a NAAT were
Pelvic inflammatory disease following chlamydia testing
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Fig 1. Cohort formation. NAAT, Nucleic Acid Amplification Test; PID, pelvic inflammatory disease.
https://doi.org/10.1371/journal.pmed.1002483.g001
Table 1. Description of the study cohort (1998–2001) by chlamydia test type.
Overall Chlamydia test type Chi-squared*
Non-NAAT NAAT
n % n % (95% CI)* n % (95% CI)~
Overall 272,105 150,248 121,857
Age group (years) 15–24 134,971 49.60 70,786 47.11 (46.86–47.37) 64,185 52.67 (52.39–52.95)
25–34 137,134 50.40 79,462 52.89 (52.63–53.14) 57,672 47.33 (47.05–47.61) <0.001
Year 1998 87,365 32.11 66,857 44.50 (44.25–44.75) 20,508 16.83 (16.62–17.04)
1999 68,737 25.26 43,600 29.02 (28.79–29.25) 25,137 20.63 (20.40–20.86)
2000 62,760 23.06 23,147 15.41 (15.22–15.59) 39,613 32.51 (32.24–32.77)
2001 53,243 19.57 16,644 11.08 (10.92–11.24) 36,599 30.03 (29.78–30.29) <0.001
STI clinic in laboratory area No 64,774 23.80 31,409 20.90 (20.70–21.11) 33,365 27.38 (27.13–27.63)
Yes 207,331 76.20 118,839 79.10 (78.89–79.30) 88,492 72.62 (72.37–72.87) <0.001
Chlamydia result Negative 254,752 93.62 141,516 94.19 (94.07–94.31) 113,236 92.93 (92.78–93.07)
Positive 17,353 6.38 8,732 5.81 (5.69–5.93) 8,621 7.07 (6.93–7.22) <0.001
Repeat chlamydia test No 210,215 77.26 116,306 77.41 (77.20–77.62) 93,909 77.06 (76.83–77.30)
Negative 58,406 21.46 32,210 21.44 (21.23–21.65) 26,196 21.50 (21.27–21.73)
Positive 3,484 1.28 1,732 1.15 (1.10–1.21) 1,752 1.44 (1.37–1.51)
PID by 12 months No 270,373 99.36 149,208 99.31 (99.27–99.35) 121,165 99.43 (99.39–99.47)
Yes 1,732 0.64 1,040 0.69 (0.65–0.73) 692 0.57 (0.53–0.61) <0.001
Abbreviations: PID, pelvic inflammatory disease; STI, sexually transmitted infection
*% of all non-NAATs; ~ % of all NAATs; ^ comparison by test type of 15-24/over 25; 1998, 1999, 2000, 2001; STI clinic in laboratory area yes/no; chlamydia
result positive/negative; repeat chlamydia test no/negative/positive, PID yes/no
https://doi.org/10.1371/journal.pmed.1002483.t001
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more likely to be younger, tested after 1998, tested by laboratories in areas without an STI clinic,
to have a positive index test, and to have a positive repeat test (Table 1).
Overall, 1,732 (0.64%) women had a hospital healthcare presentation for PID within 12
months of their chlamydia test. Over half (52.19% [n = 904]) of women diagnosed with PID
were inpatients, 25.40% (n = 440) were outpatients and 20.44% (n = 354) were treated in emer-
gency departments (the location was unknown for 1.96% [n = 34]). There was no difference in
the proportion of women with a positive test who progressed to PID within 12 months by test
type (0.78% non-NAAT and 0.81% NAAT, p = 0.805, Fig 2), but a higher proportion of
women progressed to PID following a negative non-NAAT compared to a negative NAAT
(0.69% non-NAAT and 0.55% NAAT, p< 0.001).
Test positivity was 18% higher following a NAAT compared to a non-NAAT (absolute dif-
ference 1.26%, equal to 7.07% minus 5.81%). Therefore, compared to women tested with a
NAAT, we estimate that 1.26% (equal to the difference in test positivity) of women tested
using a non-NAAT had an undiagnosed chlamydia infection and an additional 0.12% (equal
to 0.69% minus 0.57%) were diagnosed with PID. Therefore, the estimated risk of progression
from undiagnosed chlamydia infection to PID within 12 months is 9.52% (95% CI 9.30–9.68),
and there would be an estimated 120 excess cases of PID per 100,000 women tested with a
non-NAAT compared to a NAAT.
The unadjusted risk of PID within 12 months of a chlamydia test was significantly higher in
women tested with a non-NAAT, tested in 1998 compared to 2001, aged over 25, and with a
positive rather than a negative index test (odds ratio [OR] 1.27 [95% CI 1.07–1.52]) (Table 2).
The unadjusted risk of PID in the overall cohort became significantly higher at age 29 (S2
Table). The adjusted risk of PID was 32% higher in women over 25 compared with under 25
years (AOR 1.32 [1.20–1.46]), and 14% lower in women tested in 2001 compared with 1998
(AOR 0.86 [0.74–1.00]) and following a NAAT rather than a non-NAAT (AOR 0.86 [0.78–
0.96]).
Fig 2. Crude risk of PID by 12 months by test result and test type. NAAT, Nucleic Acid Amplification Test;
PID, pelvic inflammatory disease.
https://doi.org/10.1371/journal.pmed.1002483.g002
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Stratifying the analysis by test result demonstrated that for women with a positive test (pre-
sumably treated) there was no difference in the risk of PID by 12 months by test type (AOR
1.22 [0.85–1.75]). However, women with a negative test (presumably untreated) had a 17%
lower risk of PID following a NAAT compared to a non-NAAT (AOR 0.83 [0.75–0.93]).
In a further stratified model including the first repeat chlamydia test within 12 months,
women with a positive index test had a 62% lower risk of PID following a negative repeat test
compared to women without a repeat test (AOR 0.38 [0.26–0.57]) (S3 Table). For women with
a negative index test, having a repeat test was not significantly associated with PID.
Table 2. Unadjusted and adjusted logistic regression analysis of PID by 12 months by chlamydia test type, age, year of test and laboratory area,
overall, and stratified by chlamydia status.
Number of
women
Women with
PID at 12 months
Unadjusted logistic regression Adjusted logistic regression
OR 95% CI p-value AOR 95% CI p-value
a. Overall
Chlamydia test type Non-NAAT 150,248 1,040
NAAT 121,857 692 0.82 0.74–0.90 <0.001 0.86 0.78–0.96 0.005
Age group (years) 15–24 134,971 735
25–34 137,134 997 1.34 1.22–1.47 <0.001 1.32 1.20–1.46 <0.001
Chlamydia test year 1998 87,365 579
1999 68,737 488 1.07 0.95–1.21 0.261 1.08 0.96–1.23 0.191
2000 62,760 382 0.92 0.81–1.04 0.195 0.97 0.85–1.11 0.687
2001 53,243 283 0.80 0.69–0.92 0.002 0.86 0.74–1.00 0.046
STI clinic in laboratory area No 64,774 428
Yes 207,331 1,304 0.95 0.85–1.06 0.374 0.91 0.82–1.02 0.114
Chlamydia test result Negative 254,752 1,594
Positive 17,353 138 1.27 1.07–1.52 0.007 not included in model
b. Chlamydia negative
Chlamydia test type Non-NAAT 141,516 972
NAAT 113,236 622 0.80 0.72–0.88 <0.001 0.83 0.75–0.93 0.001
Age group (years) 15–24 121,996 637
25–34 132,756 957 1.38 1.25–1.53 <0.001 1.37 1.24–1.52 <0.001
Chlamydia test year 1998 82,458 538
1999 64,532 444 1.05 0.93–1.20 0.406 1.07 0.94–1.21 0.299
2000 58,398 354 0.93 0.81–1.06 0.281 0.99 0.86–1.14 0.934
2001 49,364 258 0.80 0.69–0.93 0.003 0.87 0.74–1.01 0.075
STI clinic in laboratory area No 60,008 396
Yes 194,744 1,198 0.93 0.83–1.04 0.224 0.89 0.80–1.00 0.055
c. Chlamydia positive
Chlamydia test type Non-NAAT 8,732 68
NAAT 8,621 70 1.04 0.75–1.46 0.805 1.22 0.85–1.75 0.281
Age group (years) 15–24 12,975 98
25–34 4,378 40 1.21 0.84–1.75 0.308 1.19 0.82–1.73 0.351
Chlamydia test year 1998 4,907 41
1999 4,205 44 1.25 0.82–1.92 0.298 1.24 0.80–1.90 0.338
2000 4,363 28 0.77 0.47–1.24 0.280 0.72 0.43–1.19 0.202
2001 3,879 25 0.77 0.47–1.27 0.304 0.72 0.43–1.23 0.232
STI clinic in laboratory area No 4,766 32
Yes 12,587 106 1.26 0.84–1.87 0.259 1.23 0.83–1.84 0.308
Abbreviations: AOR, adjusted odds ratio; OR, odds ratio; PID, pelvic inflammatory disease; STI, sexually transmitted infection
https://doi.org/10.1371/journal.pmed.1002483.t002
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Discussion
Women with a negative chlamydia test had a 17% higher adjusted risk of PID (absolute differ-
ence 0.14% [0.69% compared to 0.55%]) by 12 months if they were tested using a non-NAAT
compared to a NAAT, but there was no difference in the risk of PID following a positive chla-
mydia test, supporting our hypothesis. This is presumably due to the higher proportion of false
negative tests from less sensitive non-NAATs and we estimate that 18% of chlamydia infec-
tions in women tested with a non-NAAT went undiagnosed. This study suggests that the risk
of progression to PID following an untreated infection was 9.52%. We quantify the health
impact of using less sensitive chlamydia diagnostic tests as an excess 120 cases of PID per
100,000 women tested, which provides further evidence for restricting the use of non-NAATs
and other less sensitive diagnostic tests.
This is the first published comparison of the risk of PID following chlamydia testing that
takes into account diagnostic test type. There are several factors that have the potential to con-
tribute to the observed excess risk of PID following a negative non-NAAT compared to a
NAAT. Firstly, a higher proportion of women tested with non-NAATs were from the older
age group compared to the younger age group. PID risk is known to increase with age but the
increased risk of PID remained after adjustment for age [17]. Secondly, non-NAATs were
more common in the earlier time interval but it is unlikely that there were PID risk factors
(e.g., prevalence of non-chlamydia causes of PID) specific to this period that resolved by 2001
and the association remained in the adjusted analysis. Thirdly, there is the potential for bias in
the application of chlamydia diagnostic test type by PID risk or other unmeasured confound-
ers. However, the choice of diagnostic test was undertaken in the laboratory (not by the clini-
cian), and each laboratory usually changed from non-NAATs to NAATs at a discrete time as
machinery was replaced, therefore with only a short test overlap until the old test was closed
down. The association remained after adjustment for the presence of an STI clinic in the catch-
ment of laboratories.
Therefore, the most likely explanation for a difference in the risk of PID by test type follow-
ing a negative chlamydia test is the difference in test performance and the proportion of undi-
agnosed infections. In this cohort, chlamydia test positivity was 18% higher in women tested
with a NAAT compared to those tested with a non-NAAT (7.07% compared to 5.81%), which
is broadly in keeping with the reported 65%–75% sensitivity of non-NAATs compared to
NAATs [5,6].
NAATs are universally recommended for the diagnosis of chlamydia in sexually active
adults but their use is infrequent in a significant minority of European countries (n = 9/28) [3].
Data collected from 28 European countries in 2012 by the European Centre for Disease Pre-
vention and Control found that NAATs were unavailable in the public sector in five countries
and at least four countries used non-NAATs for the majority of chlamydia diagnostic tests. It
is likely that the higher price of NAATs compared to non-NAATs is at least partly contributing
to the reported deviation from international guidance. In addition to use by public-sector
authorities, EIA chlamydia tests are easily available for purchase online and in-person in many
countries. It can be difficult to access information about the test, including its performance,
which raises challenging questions about the regulation of online diagnostic tests.
Syndromic management of vaginal discharge is widely applied in low-resource settings
where diagnostic tests are unavailable [13]. This approach generally leads to an overdiagnosis
of chlamydia in uninfected women and undertreatment of those who are asymptomatic (esti-
mated to be 80% of all infections) [2]. A recent expert commission supports the development
of point-of-care tests (POCTs) for use in low-resource settings as a major player in the pathway
to improved chlamydia control [2]. But current efforts are hampered by the poor performance
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of POCTs (sensitivity in women 22.7%–93.8%, specificity 89.0%–100%) [2]. The WHO is plan-
ning to develop guidance on STI laboratory diagnosis and screening in 2017/2018. We hope
that this will address the challenge of balancing the risks of using less sensitive diagnostic tests
against syndromic management approaches in the context of resource availability and chla-
mydia control impact [9].
Of further relevance to chlamydia control policy, our supplementary analysis suggests that
the age at which the risk of PID increased was 29 years, which is older than the cutoff (25
years) commonly used in chlamydia testing guidelines. This interesting finding warrants fur-
ther exploration.
In this analysis we made crude assumptions about the underlying prevalence of chlamydia
infection and the number of women at risk of PID in the non-NAAT group to estimate that
the risk of progression to PID following an undiagnosed infection was 9.52% (9.30–9.68). This
estimate is remarkably consistent with the most robust observed risk of 9.46% (2.79–16.13)
from the Prevention Of Pelvic Infection (POPI) Randomised Controlled Trial (RCT) [18].
This similarity in result would suggest that the estimates are approximating a true underlying
biological risk. However, cohort studies of the risk of complications following chlamydia infec-
tion are hampered by the unknown impact of unmeasured confounders including undiag-
nosed repeat chlamydia infections, other incident STIs, and diagnostic biases. A further
methodological challenge is that all subsequent diagnoses of PID within the timeframe are
attributed to the incident chlamydia infection, which is likely to overestimate the true biologi-
cal association. It is important to acknowledge that some of these limitations can be considered
to apply equally within the POPI RCT as women were not repeatedly tested for STIs during
follow-up.
We agree that parameter estimates obtained from cohort studies should be interpreted cau-
tiously. However, this is the second example of the Danish Chlamydia Study producing esti-
mates of the risk of complications following chlamydia that are consistent with other study
designs. In a recent analysis, our estimate of the population excess fraction of chlamydia on
PID was consistent with estimates from a multi-parameter evidence synthesis [19]. We suggest
that the consistency between our estimates and those of others support the view that cohort
studies are a valid and informative study design in this context.
For completeness, we should consider that NAATs are not without their critics. Hadgu and
Sternberg argue that the true specificity of NAATs is lower than that commonly reported and
that the risk of progression to PID is lower following NAATs compared to other diagnostic
test types because NAATs can detect small quantities of genetic material that may be associated
with infection of lower pathogenic potential [20]. Our study does not support this hypothesis
as we found no difference in the risk of progression to PID following a positive diagnostic test
(NAAT 0.81% [0.62–1.00] versus non-NAAT 0.78% [0.59–0.96]).
The data used in this study was drawn from an unselected dataset that contains complete
ascertainment of chlamydia tests performed in public laboratories in Denmark (1992–2011).
There are no private microbiology laboratories in Denmark, therefore the study cohort is rep-
resentative of the national population of women aged 15–34 years who were tested for chla-
mydia. However, within this representative cohort, there is the potential for a systematic
difference in the clinical risk profile of women tested by CML because only five CMLs had an
STI clinic in their catchment at the time of the study. These CMLs are situated in large metro-
politan areas. In the study dataset the proportion of tests performed using a NAAT varied
from 5.5% to 100% for the CMLs with STI clinics in their catchment, but as a group this pro-
portion was more similar to those observed in CMLs without STI clinics and the overall cohort
(42.7%; 51.5%, and 44.8% respectively). We are not able to explore this potential bias further
because data on the source of the chlamydia test (e.g., STI clinic or primary care) or the clinical
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indication for the test (e.g., symptomatic or asymptomatic) is not available. To control for
potential confounding between test type and PID, CML was included in the adjusted analysis.
We applied exclusion criteria to improve the accuracy of chlamydia exposure categorisa-
tion. The coding in the original laboratory data did not allow identification of specific manu-
facturers’ tests, therefore we categorised chlamydia test type broadly into NAAT and non-
NAAT (excluding culture and microscopy). Our analysis assumes a homogenous performance
of diagnostic tests within a category.
A four-year time interval that spanned the introduction of NAATs in Denmark was chosen
to maximise the study population size whilst limiting the potential for other relevant secular
changes. The study cohort represents approximately 39.0% of Denmark’s female population,
15–34 years (n = 696,987 on 1st January 2000) [15,21]. Generalisation of the findings from this
analysis to the contemporary setting may be compromised if intervening updates to chlamydia
testing policies have led to a change in the composition (demographic or risk) of the popula-
tion being tested for chlamydia.
We used a broad ICD-10 definition of PID that is consistent with comparable research. The
ICD-10 codes included in the final dataset were all within the range N70–74.4. Healthcare presen-
tations with a diagnostic code for PID were obtained from the hospital setting (emergency depart-
ment, outpatient and inpatient). Data on cases of PID that were only seen in primary/community
care were not available, therefore our estimates of the absolute risk of PID following chlamydia
are likely to underestimate the true risk. We consider that the PID events included in this study
will represent the more severe disease in the population and therefore potentially the most signifi-
cant events in terms of future reproductive health. The incomplete ascertainment is unlikely to be
biased by chlamydia test type. We excluded women who were diagnosed with PID on the same
date as their index chlamydia test as this is independent of chlamydia test type. We also excluded
women with a past history of PID to reduce any potential biases in future risk.
Chlamydia exposure status in this cross-sectional study is based on a single diagnostic test
result and we assume that all diagnosed infections were treated. We did not apply exclusion
criteria based on women’s previous history of chlamydia testing or infection. We assume that
the distribution of both diagnosed and undiagnosed previous chlamydia infection (before
1998) would be independent of chlamydia test type.
This analysis also assumes that there is a causal relationship between the index chlamydia
infection (diagnosed or undiagnosed) and subsequent PID. To improve this assumption, we
limited episodes of PID to those within 12 months of the chlamydia test as the estimated dura-
tion of an untreated chlamydia infection is in the order of 15 months and RCTs report the risk
of PID at 12 months after the test [22,23]. This assumption is likely to overestimate the mea-
sured strength of association. We were able to adjust the analysis for test year, age, laboratory
area, and repeat chlamydia test but data on other confounders were not available (e.g., indica-
tion for the chlamydia test (symptomatic or asymptomatic); antibiotic use; individual level
incidence of other causes of PID (e.g., other STIs); healthcare seeking behaviour). It is unlikely
that these confounders are associated with diagnostic test type.
Conclusion
NAATs have been the recommended test type for the diagnosis of chlamydia in sexually active
adults for over a decade due to their superior performance over non-NAATs. We found that
women with a negative chlamydia test had a 17% higher risk of PID by 12 months if they were
tested using a non-NAAT compared to a NAAT and estimate that using non-NAATs will
result in an additional 120 cases of PID per 100,000 tested women. This is presumably due to
the higher proportion of false negative tests. This study has quantified the positive impact on
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women’s reproductive health from using accurate chlamydia diagnostic tests and provides fur-
ther evidence for restricting the use of inferior non-amplified assays including antigen-based
diagnostic tests.
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